Navigation Links
Palatin Technologies, Inc. Reports Fiscal Year 2008 Second Quarter Results; Teleconference and Webcast to be held on February 11, 2008
Date:2/11/2008

r additional information regarding Palatin, please visit Palatin Technologies' website at http://www.palatin.com.

Forward-looking Statements

Statements about the Company's future expectations, including statements about its development programs, proposed indications for its product candidates, pre-clinical activities, marketing collaborations, and all other statements in this document other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements shall be subject to the safe harbors created thereby. Palatin's actual results may differ materially from those discussed in the forward-looking statements for various reasons, including, but not limited to the Company's ability to fund development of its technology, ability to establish and successfully complete clinical trials and pre-clinical studies and the results of those trials and studies, dependence on its partners for certain development activities, need for regulatory approvals and commercial acceptance of its products, ability to recommence marketing and gain commercial acceptance of NeutroSpec(R), ability to protect its intellectual property, and other factors discussed in the Company's periodic filings with the Securities and Exchange Commission. The Company is not responsible for updating its disclosure for events that occur after the date of this press release.

PALATIN TECHNOLOGIES, INC.

Consolidated Statements of Operations

(unaudited)

Three Months Six Months

Ended December 31, Ended December 31,


'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Palatin Technologies to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
2. Ingen Technologies, Inc. Press Release Retraction
3. ReBuilder Medical Technologies, Inc. Expands R&D of New Products
4. ReBuilder Medical Technologies, Inc. Announces Televised Broadcast
5. ReBuilder Medical Technologies, Inc. 4th Quarter Sales Increase 100% Exceeding Projections
6. ReBuilder Medical Technologies, Inc. Reports Doubled Profits for October
7. Dr. Warren Wasiewski Appointed Chief Medical Officer of Neurobiological Technologies, Inc.
8. ReBuilder Medical Technologies, Inc. Announces Record Sales Month
9. ISTO Technologies, Inc. Appoints Blake Miles as Vice President of Sales
10. MagStar Technologies, Inc. Announces Third Quarter 2007 Results
11. ReBuilder Medical Technologies, Inc. Celebrates Five Years and 50,000th Shipment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... glue directly on the nerve stumps, but this method ... glue to easily invade the nerve ends. Ordinarily, nerve ... the nerve ends into the conduit because the nerve ... and co-workers from the General Hospital of Chinese PLA ... defined the best parameters for its use through in ...
(Date:8/28/2014)... can be treated with nasal septum cells. Researchers at ... that cells taken from the nasal septum are able ... and can thus repair articular cartilage defects. The nasal ... joint environment is associated with the expression of so-called ... has published the research results together with the ...
(Date:8/28/2014)... One in every 200 Ontarians has been diagnosed with ... living with the disease increasing by 64 per cent ... researchers at the Institute for Clinical Evaluative Sciences (ICES), ... Ottawa Hospital Research Institute. That puts Ontario in the ... The study, published this week in Inflammatory Bowel ...
(Date:8/28/2014)... rheumatoid arthritis patients in the study who were on ... not take them as prescribed in the first six ... from 60 hospitals around the UK involved in the ... for Genetics and Genomics at The University of Manchester, ... the drugs correctly, known as ,non-adherence, reduced their effectiveness ...
(Date:8/28/2014)... 28, 2014 BCC Research ( http://www.bccresearch.com ... SYSTEMS: TECHNOLOGIES AND GLOBAL MARKETS , the global market ... in 2013. Driven by the need for replacement of ... in emerging geographies, the market is expected to grow ... (CAGR) of 8.5% from 2013 through 2018. , While ...
Breaking Medicine News(10 mins):Health News:From nose to knee: Engineered cartilage regenerates joints 2Health News:Ontario has one of the highest rates of IBD in the world 2Health News:Arthritis patients failing to take expensive medication, according to new research 2Health News:Global Market for Surgical Navigation Systems Expected to Reach $631.9 Million in 2018; ENT Systems Segment Leading With 10.4% CAGR 2Health News:Global Market for Surgical Navigation Systems Expected to Reach $631.9 Million in 2018; ENT Systems Segment Leading With 10.4% CAGR 3
... NEW YORK (Nov. 22 2009) -- Physician-scientists from Weill Cornell ... to be a powerful target for the treatment of non-Hodgkin,s ... blood cells. By exploiting this mechanism, researchers have been able ... animal models. Promising results have led to the design ...
... ... can be both fun and joyous. It can also be stressful and tiring ... foods -- factors that can, over time, increase your risk of cancer. That,s ... 10 Food Tips that can help ensure a happier, more healthful holiday season, ...
... , WASHINGTON, Nov. 21 DNC Chairman ... to begin full debate of health insurance reform legislation. ... Senate took another historic step on the road to enacting ... will now have an opportunity to debate the health reform ...
... , , Association Discusses Key ... Reform , ST. CHARLES, Ill., Nov. 21 ... Affordable Health Care for America Act (H.R. 3962), and the ... decisive steps to fix our nation,s broken health care system. ...
... , ... addictive game, SplitWords, is now available on the iPhone and iPod Touch. , ... Mountain View, CA (PRWEB) November 21, 2009 ... iPod Touch. Split Words is designed to help banish that ,tip of the tongue, syndrome ...
... , Pioneering Neurologist Closer to Understanding ... Dr. Jeremy Schmahmann, Professor of Neurology at Harvard Medical ... Boston, on Thursday, November 19, presented his laboratory,s research ... the launch of the MINDlink Foundation. , Dr. Schmahmann ...
Cached Medicine News:Health News:New cancer target for non-Hodgkin's lymphoma 2Health News:Top 10 Food Tips for the Holidays from the National Foundation for Cancer Research 2Health News:Top 10 Food Tips for the Holidays from the National Foundation for Cancer Research 3Health News:Democratic National Committee Chairman Tim Kaine's Statement on the Senate's Vote to Proceed to Full Floor Debate of Health Insurance Reform Legislation 2Health News:AARP Hosts Rep. Bill Foster In Health Care Reform Forum 2Health News:HAPPYneuron releases iPhone Brain Game 2Health News:HAPPYneuron releases iPhone Brain Game 3Health News:MINDlink Foundation Launches to Connect the Cerebellum to Cures 2
(Date:8/28/2014)... Aug. 28, 2014 Amgen (NASDAQ: ... License Application (BLA) to the U.S. Food and Drug ... of high cholesterol. Evolocumab is an investigational fully human ... (PCSK9), a protein that reduces the liver,s ability to ... the blood. 1 ­ ...
(Date:8/28/2014)... -- Rx Safes, Inc., the manufacturer of fingerprint recognition home ... new war on drugs to reduce prescription drug abuse, ... than 2,500 children a day experiment with prescription drugs ... accessed from unsecured medicine cabinets, closets and drawers.  While law ... Safes will address the new age drug dealer in ...
(Date:8/28/2014)... 28. August 2014 Sequent ... der Patientenrekrutierung für eine IDE-Pivot-Studie („IDE" ... Beurteilung der Sicherheit und Wirksamkeit des ... („WEB") bekanntgegeben. Adam Arthur, MD, Dozent an ... Neurosurgery/Semmes-Murphey Clinic, und Hauptprüfarzt der WEB-IT-Studie, ...
Breaking Medicine Technology:Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 2Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 3Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 4Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 5Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 6Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 7Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 8Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 9Rx Safes, Inc. Announces New War On Drugs 2Sequent Medical kündigt Start einer IDE-Studie für das WEB System zur Embolisation von Aneurysmen bekannt 2Sequent Medical kündigt Start einer IDE-Studie für das WEB System zur Embolisation von Aneurysmen bekannt 3
... ROG; OTCQX: RHHBY) announced plans today to expand its coagulation ... outpatient clinics with the development of a full line of ... is expected to be introduced in the U.S. and Canada ... Roche Diagnostics is the global market leader in ...
... ORLANDO, Fla., Oct. 4, 2011 The benefits of a ... Now, new research has emerged relating to the role gender ... Gender Differences in a Naturalistic Observational Study of Sleep ... the annual Obesity Society meeting in Orlando, Florida this week. ...
Cached Medicine Technology:Roche to Expand Coagulation Testing Portfolio, Develop New Systems for Diagnostic Laboratories in US and Canada by 2014 2Research Presented at The Obesity Society Meeting Shows Link Between BMI and Sleep Patterns 2Research Presented at The Obesity Society Meeting Shows Link Between BMI and Sleep Patterns 3
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
Medicine Products: